C-7KFLallogeneic neural cell therapy, GABAergic interneurons, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
What does it take to bring a cure closer? The California Institute for Regenerative Medicine (CIRM) introduces a new quarterly speaker series, Closer to Cures, featuring presentations from our dedicated grantees that showcase their journey from research to potential FDA approval. This program brings updates directly from the forefront of medical innovation, with a special emphasis on therapies currently in clinical trials. Featured speaker Cory R. Nicholas, PhD, of Neurona Therapeutics, shares some of the latest news on the cell therapy they are developing to treat epilepsy.
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Dr. Cory Nicholas, Ph.D. is Chief Scientific Officer at Neurona Therapeutics, whose mission is, in part, an extension of Dr. Basbaum’s work funded by the FPRF. It continues to develop a human inhibitory interneuron therapeutic for the treatment of neuropathic pain syndromes. Prior to co-founding Neurona, he was a faculty member in the Department of Neurology at the University of California, San Francisco, where his research program was focused on investigating the ontogeny of human cortical interneurons. Corey pioneered methods to derive interneuron precursors from human pluripotent stem cells for transplantation into multiple animal models of neurological disease. Neurona and the FPRF share a bold vision to achieve pain-free disease modification. Corey is also a Co-Lead Investigator with Dr. John Neubert on the FPRF research project “Evaluation of a Cellular Therapeutic for the Treatment of Trigeminal Pain.” This project is designed to test whether the Neurona interneuron cell therapy
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy Press Release Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy – Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 EPIC (EPIlepsy Cell therapy) trial as the primary basis for a future NRTX-1001 Biologics License Application – The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with drug-resistant mesial temporal lobe epilepsy Sa … e are delighted to be moving NRTX-1001 one step closer to a potential marketing application.” “People living with drug-resistant seizures face a significant burden due to the substantial risks of ongoing seizures. They often have limited therapeutic options, such as surgery to remove or ablate the seizure-prone region of the brain, which can cause irreversible impairment of memory and other neurocognitive functions,” explained Manher A. Joshi, M.D., Neurona& … e. The Phase 1/2 unilateral MTLE clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355). The FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 in June 2024 based on positive clinical data from the ongoing Phase 1/2 trial in unilateral MTLE. For more information about Neurona, visit: www.neuronatherapeutics.com . Investor Contact: Laurence Watts New Street Investor Re
UCB completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science | UCB Skp to main content Main navigation Menu Innovation Innovation Overview Capabilities Innovation is Pipeline Drug discovery Clinical studies Publications You might be interested in... Page Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity Page Publications - A dedicated space where we share a collection of our scientific peer-reviewed... Page Pipeline - Check out our clinical development pipeline spanning several t … Direct access to our latest annual report Story 9 Feb 2026 UCB Community Health Fund enters a new phase Page UCBCares® - Discover what UCBCares® is about and the services they offer Newsroom Newsroom Overview Press releases Our stories Resources Contact details You might be interested in... Press Release 11 Mar 2026 BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study... Press Release 26 Feb 2026 Strong Execution Fueling Sustaine
Neurona Therapeutics Appoints James Stutz as CFO and CBO | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Neurona Summit success story | IFEMA MADRID Access the main content Home Calendar Exhibit at IFEMA Organize your event About IFEMA Live Contact Facebook Instagram linkedin Twitter youtube TikTok Events Events Events All events Fairs Congresses Concerts Shows Exhibitions Organising and exhibiting Organising and exhibiting Organise an event Why organise an event Conventions and Congresses Concerts and Shows Exams and public examinations Services for organisers Our spaces Exhibit at IFEMA MADRID Why exhibiting Exhibitor services Expo Zone Advertising Promote your brand Legal Technical Support Abo … TikTok Language Legal Notice Privacy Policy Cookies policy Accesibility Cookies Submit
10-K FY 0001582313 false Unlimited Unlimited http://fasb.org/us-gaap/2024#LeaseholdImprovementsMember one 2045-12-31 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 One http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001582313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001582313 us-gaap:ComputerEquipmentMember 2023-12-31 0001582313 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001582313 us-gaap:PerformanceSharesMember 2024-12-31 0001582313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth companyR … the Co-Funding Option (as defined below). We will have the right to elect to co-fund the development of one product in the first indication that meets or exceeds a specified prevalence threshold, or a Major Indication, under such development plan and to receive a mid-single digit percentage increase in royalties owed on the net sales as calculated pursuant to the terms of the Collaboration Agreement, or Net Sales, of such products in the U.S., or the Co-Funding Option. If we … y with respect to one or more products or countries, then such termination will apply only to the terminated products or countries. Upon termination in certain cases, Neurocrine Biosciences has agreed to grant us licenses to certain Neurocrine Biosciences intellectual property that is reasonably necessary, and that was actually used by Neurocrine Biosciences for the development, manufacturing or commercialization of the terminated products, to research, develop and commercial … y animals and other applicable regulations; • submission to the FDA of an application for an IND, which must become effective before human clinical studies may begin; • performance of adequate and well-controlled human clinical studies according to the FDA’s regulations commonly referred to as good clinical practices, or GCPs, a
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI) Press Release Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI) – Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001 cell therapy treatment group versus 5% in the control group – Data demonstrate accurate and reproducible on-target adminis … livery device – Neurona expects to file an Investigational New Drug (IND) Application this year to begin a Phase 1/2a clinical trial in people with drug-resistant focal epilepsy SAN FRANCISCO, June 16, 2021 – Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today announced the presentation of clinical trial plans and supporting preclinical data for its lead inhibi
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manuf … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders February 8, 2024 | 8 min read Twitter LinkedIn Facebook Email Print Neurona Therapeutics today announced the successful completion of a $120 million financing co-led … Euclidean Capital, SymBiosis, Alexandria Venture Investments, Berkeley Frontier Fund, Sphera Biotech Master Fund LP, Spur Capital Partners, UCB Ventures, and UC Investments. Proceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001. NRTX-1001 is being evaluated in an ongoing open-label, single-arm Phase I/II clinical trial for treatm … atment of drug-resistant mesial temporal lobe epilepsy (MTLE) and has potential application in Alzheimer’s disease and other disorders of the nervous system. “We are excited to co-lead this financing with Viking and other committed investors to help advance Neurona’s cell therapies to address unmet needs in chronic neurological disorders,” said Raymond Kelleher, M.D., Ph.D., managing director of Cormorant and a neurologist at Massachusetts General Hospital, Harvard Medical Sc … 5135091 ). The first part of the clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355). With $5.5 billion in funding and more than 150 active stem cell programs in its portfolio, CIRM is one of the world’s largest institutions dedicated to helping people by bringing the fu
Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency Press Release Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency December 14, 2017 – Oakland, CA The California Institute for Regenerative Medicine (CIRM), the state’s Stem Cell Agency, today invested almost $24.8 million dollars in 13 different projects targeting a wide range of diseases and disorders. The investment is part of CIRM’s Discovery Quest Award Program. Quest promotes the discovery of promising new stem cell-based techn … en cure for HIV/AIDS. The 13 projects funded under CIRM’s Discovery Quest Award program are listed here: Application Title Institution CIRM COMMITTED FUNDING DISC2-10591 Preclinical development of an immune evasive islet cell replacement therapy for type 1 diabetes ViaCyte $1,470,987 DISC2-10524 Genome Editing of Sinusoidal Endothelial Stem Cells for Permanent Correction of Hemophilia A City of Hope $2,182,193 DISC2-10679 Towards hepatocyte cell replacement therapy: dev
Neurona Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Neurona Therapeutics Hired a Community College Student Website: Neurona Therapeutics Business Area(s) Neurobiology Cell and Gene Therapy Stem Cells Description Neuronal stem-cell therapies Career Page(s) Join Our Team Culture Values Benefits Visiting Scientists & Internship programs... Job
Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy July 11, 2025 | 4 min read Twitter LinkedIn Facebook Email Print SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing re … ill provide primary support for submitting a potential future Biologics License Application (BLA). For more information about Neurona, visit: www.neuronatherapeutics.com . Investor Contact: Laurence Watts New Street Investor Relations [email protected] Twitter LinkedIn Facebook Email Print Preclinical Northern California LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy June 26, 2026 · … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science April 19, 2026 | 10 min read Twitter LinkedIn Facebook Email Print Acquisition builds on UCB's 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next gener … sp; 2 min read · Nick Paul Taylor Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac Drug pricing BIO 2026: Biopharma dealmakers seek to protect ‘premium pri … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Se … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy November 5, 2025 | 4 min read Twitter LinkedIn Facebook Email Print EMA’s PRIME designation bolsters Neurona’s global developm … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline April 4, 2025 | 4 min read Twitter LinkedIn Facebook Email Print - The oversubscribed private financing round, with primary participation from Fidelity Management & Res … ngle pivotal trial and is intended to support submission of a Biologics License Application (BLA) SOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an upsized and oversubscribed $102 million financing. New and existing investors in the financing round include Fide … B Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, and Spur Capital Partners. Proceeds from the financing will be used to advance the company’s wholly owned pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead investigational candidate, NRTX-1001, for drug-resistant mesial temporal lobe epilepsy (MTLE), which is among the most common types of epil … e. The Phase 1/2 unilateral MTLE clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355). The FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 in June 2024. For more information about Neurona, visit: www.neuronatherapeutics.com . Investo
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer June 11, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today a … from the Boston University School of Medicine. He completed his internship and residency in internal medicine at Yale. About Neurona Therapeutics Neurona is developing allogeneic, off-the-shelf, regenerative neural cell therapy products with curative potential to provide long-term repair of the nervous system after a single administration. The company’s lead asset NRTX-1001, comprising GABAergic interneurons, is currently being studied for safety and efficacy in two ongoing … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society December 8, 2025 | 7 min read Twitter LinkedIn Facebook Email Print - NON-MTS & BILATERAL MTLE: First data reported from non-MTS and bilateral MTLE subje … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer November 19, 2025 | 3 min read Twitter LinkedIn Facebook Email Print SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company focused on advancing regenerative cell therapi … played a key role in the filing and approval of the EU Marketing Authorization Application for Epidyolex as well as the U.S. approval of a supplementary NDA for the treatment of seizures associated with tuberous sclerosis complex. Earlier in his career, he held roles of increasing responsibility in clinical development at Eli Lilly and Co., Amgen, Takeda Pharmaceuticals, Annexon Biosciences and Orexigen Therapeutics. Dr. Dunayevich holds a medical degree from the University … vich holds a medical degree from the University of Buenos Aires and completed a residency in psychiatry at the University of Cincinnati Medical Center. He subsequently was board certified in General Psychiatry by the American Board of Psychiatry and Neurology (ABPN) and was a clinical investigator and faculty at the University of Cincinnati prior to joining the pharmaceutical industry. About Neurona Therapeutics Neurona is developing allogeneic, off-the-shelf, regenerative ne … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate September 11, 2024 | 3 min read Twitter LinkedIn Facebook Email Print SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company … t the California Institute for Regenerative Medicine (CIRM) has awarded a $3.8M grant to support the development of a next generation neural cell therapy candidate. “We’re grateful for the ongoing partnership with CIRM to help support the development of novel regenerative cell therapy candidates for the prospective treatment of epilepsy and other neurological disorders,” said Cory R. Nicholas, Ph.D., Neurona’s Chief Executive Officer and Co-Founder. “We believe this expanded … unmet medical need in drug-resistant epilepsy.” “CIRM is delighted to make this award to Neurona Therapeutics in view of the highly encouraging initial data from its ongoing Phase 1/2 clinical trial in adults with drug-resistant epilepsy. Today’s grant brings CIRM’s cumulative commitment to the company to $18.5M across five separate grants,” said Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM. “This award highlights the promise of regenerative medicine … e Phase 1 of the unilateral MTLE clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355). The FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 in June 2024 based on positive clinical data from the ongoing Phase 1/2 trial in unilateral MT
Brain’s adult stem cells born early Skip to content Subscribe today Every print subscription comes with full digital access Subscribe Now Menu All Topics Health Humans Anthropology Health & Medicine Archaeology Psychology View All Life Animals Plants Ecosystems Paleontology Neuroscience Genetics Microbes View All Earth Agriculture Climate Oceans Environment View All Physics Materials Science Quantum Physics Particle Physics View All Space Astronomy Planetary Science Cosmology View All Magazine Menu All Stories Multimedia Reviews Puzzles Collections Educator Portal Century of Science Unsung
Libby Nunan, Author at The Column Group - Page 11 of 12 Skip to content Main Menu Meet TCG Overview Cultivating New Frontiers of Science TCG Team Our Portfolio In the News Join our Ecosystem Contact Us Investor Login Contact Us Investor Login Libby Nunan Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology Annual Meeting Portfolio News / By Libby Nunan Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of … an Academy of Neurology Annual Meeting Read More » Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease Portfolio News / By Libby Nunan Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease Read More » Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline Portfolio News / By Libby Nunan N
Jobs at Neurona Therapeutics | California | Consider You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Sign In Powered by Consider Privacy Terms
UCB cuts $1.15bn deal to buy epilepsy biotech Neurona | pharmaphorum Skip to main content Friday 26 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & Devel
Neurona Therapeutics investment analysis --> --> Bay Bridge Bio Menu Blog About Contact Neurona Therapeutics investment analysis February 14, 2024 This is not investment advice. We used AI and automated software tools for most of this research. A human formatted the charts based on data / analysis from the software, prompted the AI to do some editing, and did some light manual editing. We did some fact checking but cannot guarantee the accuracy of everything in the article. We do not have a position in or an ongoing business relationship with the company. Overview Overview: Neurona Therapeutic … ential. However, significant gaps remain in translating these findings to human application, with the need for more comprehensive studies on long-term safety, efficacy, and optimization of transplantation methodologies. Bridging these gaps is crucial for moving forward from the conceptual stage to practical therapeutic applications. Clinical trial overview The study design for NRTX-1001, aimed at addressing drug-resistant unilateral mesial temporal lobe epilepsy, embarks on a … ss established compared to MS or SCI. Key Limitations and Future Directions The application of myelinating glial cell therapy across these conditions underscores the potential broad therapeutic impact of targeting myelination pathways. However, challenges such as cell delivery methods, long-term survival and integration of transplanted cells, immune rejection, and precise targeting of therapy remain significant hurdles. Moreover, clinical trials are necessary to establish saf … n their causes, affected populations, and disease progression, complicating the application of a singular therapeutic approach like myelinating glial cell therapy. This heterogeneity means that a therapy effective for one condition might not be effective for another, and even within a single condition, patient response can vary significantly. Technical and Ethical Considerations: The production and use of glial cells, especially those derived from embryonic stem cells or indu … ls and the host’s immune system presents a significant hurdle to the successful application of myelinating glial cell therapy. In summary, while the therapeutic rationale for myelinating glial cell therapy is strongly supported by basic and preclinical research, demonstrating clear, consistent clinical benefits for patients remains a challenge. F
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October Press Release Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October San Francisco, CA, October 10, 2023 – Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Jefferies Inaugural Biotech CNS/Neuro Summit at 1:00 pm ET on Thursday, October 12, 2023
Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting Press Release Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting – Oral presentation will outline design of first ever Phase 1/2 clinical trial of regenerative human cell therapy in epilepsy – Presentations will detail single-cell transcriptomic profiling of NRTX-100 … t stage of the clinical trial is supported by a recently announced $8.0 million grant from the California Institute for Regenerative Medicine (CIRM) (CLIN2-13355). About NRTX-1001 NRTX-1001 is a regenerative neural cell therapy derived from human pluripotent stem cells. The fully-differentiated neural cells, called interneurons, secrete the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Delivered as a one-time dose, the human interneurons are intended to integrat
Neurona Therapeutics Secures $3.8M CIRM Grant for Next-Gen Neural Cell Therapy Products Data Feature Plans Request Demo Sign Up for Free Neurona Therapeutics Secures $3.8M CIRM Grant for Next-Gen Neural Cell Therapy 14 September 2024 Neurona Therapeutics , a clinical-stage biotherapeutics firm focused on regenerative cell therapies for nervous system disorders, has been awarded a $3.8 million grant by the California Institute for Regenerative Medicine (CIRM). This grant aims to support the development of an advanced neural cell therapy candidate. Cory R. Nicholas, Ph.D., the CEO and Co-Founder … sident of Therapeutics Development at CIRM, highlighted the significance of the award, noting that it brings CIRM’s total commitment to Neurona Therapeutics to $18.5 million across five grants. She pointed out that this award underscores the promise of regenerative medicine technology, particularly Neurona’s pipeline of cell therapy candidates for patients with epilepsy and other central nervous system disorders . Earlier this year, Neurona Therapeutics presented updated data … in the future. The Phase 1 trial for unilateral MTLE has received an $8 million grant from CIRM. In June 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 based on positive clinical data from the ongoing Phase 1/2 trial in unilateral MTLE. The most recent data update was presented at the AAN Annual Meeting in April 2024. Additionally, in February 2024, Neurona raised $120 million in a private financing round co-led by Viking Global I
Join us for our upcoming speaker series, Closer to Cures, on Thursday, January 29, at 10:30 AM (PST). Hear from CIRM awardees Dr. Cory R. Nicholas, PhD, of Neurona Therapeutics and Dr. Crystal… | California Institute for Regenerative Medicine (CIRM) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this u
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference Press Release Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference San Francisco, CA, May 28, 2024 – Neurona Therapeutics , a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for the potential treatment of neurological disorders, today announced that Cory R. Nicholas, Ph.D. , Neurona’s Co-Founder and Chief Executive Officer, is scheduled to host investor meetings at the Jefferies Global Healthcare Conference being held at the Marriott Marquis
John Rubenstein M.D., Ph.D. - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile John Rubenstein M.D., Ph.D. Advisor at NEURONA THERAPEUTICS, INC John Rubenstein M.D., Ph.D. 's Executive Work History Current Advisor , Advisor Equilar on 09/06/2025 NEURONA THERAPEUTICS, INC Past To view John Rubenstein M.D., Ph.D.'s complete executive work history, sign up now John Rubenstein M.D., Ph.D. ' … received his Ph.D. and M.D. degrees in 1982 and 1986 and completed his medical residency at Stanford University. He obtained his B.S. in Chemistry from Stanford University in 1977. Dr. Rubenstein was elected to the National Institute of Medicine in 2006. Source: NEURONA THERAPEUTICS, INC on 09/06/2025 John Rubenstein M.D., Ph.D. 's Connections (13) Alessandro Bulfone MD Vice President of Operations , NEURONA THERAPEUTICS, INC Leo A. Guthart PhD Board Member , DepYmed Inc. Ja … received his Ph.D. and M.D. degrees in 1982 and 1986 and completed his medical residency at Stanford University. He obtained his B.S. in Chemistry from Stanford University in 1977. Dr. Rubenstein was elected to the National Institute of Medicine in 2006. Source: NEURONA THERAPEUTICS, INC on 09/06/2025 John Rubenstein M.D., Ph.D. 's Connections (13) Alessandro Bulfone MD Vice President of Operations , NEURONA THERAPEUTICS, INC Leo A. Guthart PhD Board Member , DepYmed Inc. Ja
Neurona Therapeutics – CIRM Skip to content Grants Management System CIRM Hub Portal Contact Search About Our Mission Our Impact Our Governing Board Strategic Goals Our Team Annual Reports For Researchers Funding Opportunities Information for Applicants Researcher Resources Our Review Process Our Programs Grants Dashboard Research and Development Education and Training Patient Access Patient Resources Stem Cell and Genetic Research From Bench to Bedside Community Outreach Clinical Trials Community Stories News and Events Press Releases Public Meetings Blog Webinars and Workshops About Ou … og Webinars and Workshops Neurona Therapeutics Return to Grants Total Awards: 6 Award Value: $32,496,237 Institution type: For profit Short Name: Neurona Therapeutics Awards to the Institution Program Type Investigator Grant Title Award Value Quest – Discovery Stage Research Projects Dr. Cory R Nicholas Development of a Cellular Therapeutic for Treatment of Epilepsy $1,616,536 Therapeutic Translational Research Projects Dr. Cory R Nicholas Development of a universal all … Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy $7,999,999 Progression Award – Discovery Stage Research Projects Dr. Cory R Nicholas Global gene expression profiling of single inhibitory neurons derived from human stem cells $202,500 Total: $32,496,237.00 Careers Administrative & Financials Accessibility Subscribe to Receive CIRM News Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. Sign Up Faceb
Neurona Therapeutics Raises $102 Million – Ysios Capital About us About us Funds Investment strategy Our portfolio The team The team Join us News & events Impact/ESG ESG Y-mpact Measure your Y-score Contact us Investors login 4 April 2025 Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline The oversubscribed private financing round, with primary participation from Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, and Cormorant Asset Management, follows con … ngle pivotal trial and is intended to support submission of a Biologics License Application (BLA) South San Francisco, CA, April 3, 2025 – Neurona Therapeutics , a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an upsized and oversubscribed $102 million financing. New and existing investors in the financing round include Fidelity Management & R … B Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital , Alexandria Venture Investments, and Spur Capital Partners. Proceeds from the financing will be used to advance the company’s wholly owned pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead investigational candidate, NRTX-1001, for drug-resistant mesial temporal lobe epilepsy (MTLE), which is among the most common types of epi … e. The Phase 1/2 unilateral MTLE clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355). The FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 in June 2024. For more information about Neurona, visit: www.neuronatherapeutics.com Contacts Investor Contact: Laurence Watts New Street Investor Relations [email protected] Downloads PDF Download - EN Re
2026 Gruber Neuroscience Prize | Neurona Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy … istinguished Professor in Child Psychiatry, for winning the Gruber Neuroscience Prize! A well-deserved achievement. We are proud to be translating some of John's many remarkable discoveries, including Rezanecel that's already making a major impact in the lives of the ~30+ patients treated to date. Way to go, John! https://lnkd.in/gWJ-8xN4 https://lnkd.in/gFV9rMxv 2026 Gruber Neuroscience Prize gruber.yale.edu 133 3 Comments Like Comment Share Copy LinkedIn Facebook X Tim Fene
Preclinical-Development-of-NRTX-1001--an-Inhibitory-Interneuron-Cellular-Therapeutic-for-the-Treatment-of-Chronic-Focal-Epilepsy Career Center AES Connect Donate supervisor_account check_circle Get Involved search search Search menu Menu Home Abstracts Abstracts Preclinical Development of NRTX-1001, an Inhibitory Interneuron Cellular Therapeutic for the Treatment of Chronic Focal Epilepsy Abstract number : 1.091 Submission category : 2. Translational Research / 2B. Devices, Technologies, Stem Cells Year : 2021 Submission ID : 1826253 Source : www.aesnet.org Presentation date : 12/9/2021 12:00: … of these studies will be submitted as part of an Investigational New Drug (IND) application to the FDA to support a Phase 1/2a clinical trial to assess the safety and preliminary efficacy of NRTX-1001 in patients with drug-resistant mesiotemporal lobe epilepsy. The proposed clinical trial design will be presented. Funding: Please list any funding that was received in support of this abstract. : CIRM (TRAN1-11611). Translational Research Contact Us Press Room AES Connect Find … ucation arrow_drop_down AES Learn Resident Courses Epilepsy and Neurophysiology Fellowship Match Membership arrow_drop_down Become a Member Get Involved In Memoriam Directory (Members Only) Give arrow_drop_down Make a Gift Planned Giving Your Dollars at Work Targeted Funds Corporate Support About arrow_drop_down About AES Publications & Reports Press Room Reach Members Epilepsy Leadership Council Contact AES arrow_upward Back to top Terms of Use Disclosure P
Gautam Banik PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Gautam Banik PhD Chief Technology Officer at NEURONA THERAPEUTICS, INC Gautam Banik PhD 's Executive Work History Current Chief Technology Officer , Chief Technology Officer Equilar on 07/30/2025 NEURONA THERAPEUTICS, INC Past To view Gautam Banik PhD's complete executive work history, sign up now Education Ph.D., Dartm
Abstract Details American Academy of Neurology: Neurology Resources | AAN AAN Publications Explore the latest content from across our publications AAN Publications Donate To Research Join The AAN Log In Education Education Education Online Learning Center CME Opportunities NeuroTracker Leadership Programs Education Awards & Scholarships Podcasts Discover learning and leadership opportunities, earn CME, and track credits. See All Research Research Research Abstracts Publications Awards Research Programs & Grants Donate to Research Explore prestigious scientific journals and award and fu
Human stem cell-derived GABAergic interneuron development reveals early emergence of subtype diversity followed by gradual electrochemical maturation | bioRxiv Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results Human stem cell-derived GABAergic interneuron development reveals early emergence of subtype diversity followed by gradual electrochemical maturation View ORCID Profile Marina Bershteyn , Hongjun Zhou , Luis Fuentealba , Chun Chen , Geetha Subramanyam , Daniel Cherkowsky , Juan Salvatierra , Meliz Sezan , Yves Maury , Steven Havlicek
Neurona Therapeutics, Inc. Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Co … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Neurona Therapeutics, Inc. - overview Established 2008 Location South San Francisco, CA, US Primary Industry Biotechnology About Based in California, US, and founded in 2014 by co-founder and CEO Cory R. Nicholas, Neurona Therapeutics, Inc. is a clinical-stage biotherapeutics company that focuses on the de … , Viking Global Investors, Ysios Capital Partners, Fidelity Investments, Sphera Fund Management, Cormorant Asset Management, Ironfire Ventures, UC Ventures, LYFE Capital, UCB Ventures, Soleus Capital, The National Institutes of Health, Symbiosis Capital Management, Berkeley Frontier Fund, and YK Bioventures for an upfront payment of USD 650 milli
Human stem cell-derived GABAergic interneuron development reveals early emergence of subtype diversity and gradual electrochemical maturation Human stem cell-derived GABAergic interneuron development reveals early emergence of subtype diversity and gradual electrochemical maturation Neuron . 2025 Oct 1;113(19):3162-3184.e10. doi: 10.1016/j.neuron.2025.06.010. Epub 2025 Jul 11. Authors Marina Bershteyn 1 , Hongjun Zhou 2 , Luis Fuentealba 2 , Chun Chen 3 , Geetha Subramanyam 2 , Daniel Cherkowsky 2 , Eric Steven Sevil
Arturo Alvarez-Buylla PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Arturo Alvarez-Buylla PhD Advisor at NEURONA THERAPEUTICS, INC Arturo Alvarez-Buylla PhD 's Executive Work History Current Advisor , Advisor Equilar on 06/12/2026 NEURONA THERAPEUTICS, INC Past To view Arturo Alvarez-Buylla PhD's complete executive work history, sign up now Arturo Alvarez-Buylla PhD 's Biograph … Álvarez-Buylla has received numerous awards including the Robert L. Sinsheimer Award in Molecular Biology, the Jacob Javits Award and the Prince of Asturias Award for Technical and Scientific Research. david blum photo David Blum, MD Senior Medical Advisor Dr. David Blum is a Senior Medical Advisor to Neurona Therapeutics having previously served as Chief Medical Officer at the Company. David has worked in clinical development positions in the pharmaceutical industry for ove … his M.D. from the University of California at San Diego and completed neurology residency and neurophysiology fellowship at the University of California at Los Angeles. stephen hauser photo Stephen Hauser, MD Professor of Neurology, UC San Francisco, Director, UCSF Weill Institute for Neurosciences Stephen L. Hauser, M.D. is the Robert A. Fishman Distinguished Professor and Chair of the Department of Neurology at the University of California, San Francisco. A neuroimmunologis … s and honors for his work, including the Jacob Javits Neuroscience Investigator Award from the NIH, the John Dystel Prize and the Charcot Award for Multiple Sclerosis Research. In April 2010 Dr. Hauser was appointed by President Obama to the Presidential Commission for the Study of Bioethical Issues charged with advising the President on issues that may emerge from advances in biomedicine and related areas of science and technology. He is a graduate of MIT (Phi Beta Kappa) an … in 1977 where his thesis advisor was Dr. Eric Kandel. He subsequently completed Residency training in Neurology at the Brigham and Women’s Hospital, Children’s Hospital, and Beth Israel Hospital in Boston. Dr. Kriegstein has received numerous awards including the Stanford University William M. Hume Faculty Scholar and two Javits Awards from the N
Dollars for Profs - Arturo Alvarez-Buylla | ProPublica Dollars for Profs Sign Up Donate Dollars for Profs Dig Into University Researchers' Outside Income and Conflicts of Interest Published Dec. 6, 2019 This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here. Dollars for Profs California University of California, San Francisco Arturo Alvarez-Buylla Filing Type Conflict of Interest Institutions must file significant disclosures to the National Institutes of Health if they determine financial rel
Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy Cell Stem Cell . 2023 Oct 5;30(10):1331-1350.e11. doi: 10.1016/j.stem.2023.08.013. Authors Marina Bershteyn 1 , Sonja Bröer 1 , Mansi Parekh 1 , Yves Maury 1 , Steven Havlicek 1 , Sonja Kriks 1 , Luis Fuentealba 1 , Seonok Lee 1 , Robin Zhou 1 , Geetha Subramanyam 1 , Meliz Sezan 1 , Er
Very proud of what Neurona has accomplished so far. Acquisition by UCB is an endorsement of the promise of cell therapy to treat nervous system disorders beginning with medically-intractable… | Arnold Kriegstein LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any
#cell #epilepsy #cell | Neurona Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Coo
Neurona Therapeutics Launches With $23.5 Million in Series A Funding to Repair Damaged Neural Circuits Press Release Neurona Therapeutics Launches With $23.5 Million in Series A Funding to Repair Damaged Neural Circuits SOUTH SAN FRANCISCO, CA - December 01, 2015 - Neurona Therapeutics Inc., a biotechnology company focused on the transplantation of selected neurons to treat intractable neurological diseases, today announced its launch with a $23.5 million Series A financing led by The Column Group. Unlike more traditional therapeutic modalities such as small molecules or antibodies, Neurona is … , PhD, VP of Preclinical Development at Neurona, filed the first successful IND application for a human pluripotent stem cell-based therapeutic as a former Senior Director at Geron Corporation. Neurona's Scientific Advisory Board features Allan Basbaum, PhD, Chair and Professor of Anatomy at UCSF; Lorenz Studer, MD, PhD, Professor and Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center; and Oscar Marin, PhD, Professor and Director of MRC
Neurona’s brain stem cell therapy shows early efficacy in epilepsy Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Portfolio News Archives - Page 11 of 76 - The Column Group Skip to content Main Menu Meet TCG Overview Cultivating New Frontiers of Science TCG Team Our Portfolio In the News Join our Ecosystem Contact Us Investor Login Contact Us Investor Login Portfolio News Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease Portfolio News / By Libby Nunan Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease Read More » Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epile
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Scientific Presentations | Neurona Therapeutics Scientific Presentations First-in-Human Study of NRTX-1001 GABAergic Interneuron Cell Therapy for the Treatment of Focal Epilepsy AES Poster | 2024 First-in-Human Study of NRTX-1001 GABAergic Interneuron Cell Therapy for Treatment of Focal Epilepsy - Emerging Clinical Trial Results AES Poster | 2023 NRTX-1001: Human inhibitory neuron cell therapy suppresses seizures and reduces histopathology in mouse model of chronic focal epilepsy with high repeatability across multiple studies and manufacturing lots SfN Poster | 2023 Behavioral analyses i
Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference Press Release Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference San Francisco, CA, March 8, 2023 – Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15 at 2:00 pm ET.
Events | Neurona Therapeutics Events Upcoming Events There are no upcoming events at this time. Archived Events Thursday, October 3, 2024 2024 William Blair’s Innovator Series: Private Biotechnology Stars Access code: Biotech24! Cory R. Nicholas, Ph.D., CEO Tuesday, March 19 at 5:00 pm ET Stifel 2024 Virtual CNS Days Cory R. Nicholas, Ph.D., CEO Thursday, February 29, 2024 Evercore ISI 2024 Emerging Biotech Conference Cory R. Nicholas, Ph.D., CEO Wednesday, February 14, 2024 at 2:00pm ET Oppenheimer 34th Annual Healthcare Lifesciences Conference Cory R. Nicholas, Ph.D.,
UCB S.A.. (4/17/26). "Press Release: UCB to Acquire Neurona Therapeutics, Advancing Its Innovative Leadership in Epilepsy through Regenerative Science". Brussels. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events European Spatial Computing Healthcare Summit 2026 Leipzig EUROMAR … holm (NLSDays 2026) BIO-Europe 2026 Cologne (Köln) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
UCB Completes Neurona Therapeutics Acquisition, Expanding Epilepsy Treatment Options | Marie T. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … undisclosed strategic investor and S3 Ventures, with participation from the T45 Fund as well as new and existing investors. The post Advanced NanoTherapies Raises Over $31 Million Series B To Advance Dual-Drug Nanoparticle-Coated Balloon Platform appeared first on Pulse 2.0. Advanced NanoTherapies Raises Over $31 Million Series B To Advance Dual-Drug Nanoparticle-Coated Balloon Platform https://pulse2.com 11 Like Comment Share Copy LinkedIn Facebook X To view or add a comment
NRTX-1001--First-in-class-Human-Inhibitory-Neuron-Cell-Therapy-for-Phase-I/II-Clinical-Investigation-in-Chronic-Focal-Epilepsy Career Center AES Connect Donate supervisor_account check_circle Get Involved search search Search menu Menu Home Abstracts Abstracts NRTX-1001: First-in-class Human Inhibitory Neuron Cell Therapy for Phase I/II Clinical Investigation in Chronic Focal Epilepsy Abstract number : 3.102 Submission category : 2. Translational Research / 2B. Devices, Technologies, Stem Cells Year : 2022 Submission ID : 2204422 Source : www.aesnet.org Presentation date : 12/5/2022 12:00:00 P … ucation arrow_drop_down AES Learn Resident Courses Epilepsy and Neurophysiology Fellowship Match Membership arrow_drop_down Become a Member Get Involved In Memoriam Directory (Members Only) Give arrow_drop_down Make a Gift Planned Giving Your Dollars at Work Targeted Funds Corporate Support About arrow_drop_down About AES Publications & Reports Press Room Reach Members Epilepsy Leadership Council Contact AES arrow_upward Back to top Terms of Use Disclosure P
Neurona Therapeutics Appoints Brad Margus to its Board of Directors Press Release Neurona Therapeutics Appoints Brad Margus to its Board of Directors San Francisco, CA, October 20, 2021 – Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has appointed Brad Margus to its board of directors. Mr. Margus brings over 30 years of company building and corporate leadership experience including over 20 years in the development of therapeutics for central nervous system (CNS) dise … y Neurona’s innovative regenerative cell therapy platform and its initial application in an off-the-shelf therapy that has the potential to broaden treatment options for people with drug resistant focal epilepsy,” said Mr. Margus. “I look forward to working with the talented Neurona team and board of directors to help build and grow the company as it brings its neural cell therapy candidates to patients as expeditiously as possible.” Mr. Margus is a co
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science | Gary Yeung, CFA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continu
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science | UCB Skip to main content UCB's Global Corporate Website Welcome to UCB in the United States Healthcare Professionals Patients Investors Facebook Twitter YouTube LinkedIn Instagram Main navigation UCB - Inspired by patients. Driven by science. Chercher Home UCB in the U.S. UCB in the U.S. U.S. Leadership Team U.S. PharmD Fellowships Patients U.S. Clinical Trials U.S. Population Health at UCB Moments that Matter Innovation U.S. Innovation Products R&D Disease Areas Disease Area
Neurona Acquired by UCB for $1.15 Billion | Rebecca "Becky" Kusko, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … s post Stem cell technology is steadily moving from research into real clinical application, with growing use in tissue repair, disease treatment and regenerative therapies. What is driving momentum is the overlap with gene editing, AI and bioengineering, which is helping researchers better understand how cells develop and respond in controlled environments. At the same time, challenges remain around regulation, scalability and manufacturing, particularly when moving from lab
UCB Proposes $650M Acquisition of Neurona Therapeutics | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe Now Stay infor
Expanded Access Program | Neurona Therapeutics Expanded Access Program Neurona Therapeutics Expanded Access Program Neurona Therapeutics (Neurona) is dedicated to developing cellular therapies that have a positive impact on patient health for serious or life-threatening illnesses/conditions of the central nervous system. Consistent with the company mission, Neurona’s development resources are focused on conducting clinical studies required by regulatory authorities to fully answer important scientific questions about the potential risks and benefits of our investigational products, and t
Terms of Use | Neurona Therapeutics Terms of Use Neurona Therapeutics Website Terms of Use Last updated March 7, 2022 Welcome, and thank you for your interest in Neurona Therapeutics, Inc. (“ Neurona ,” “ we ,” “ us ,” or “ our ”) and our website at https://www.neuronatherapeutics.com/ (the “ Site ”). These Terms (as defined below) govern only your use of the Site and not any of our other products or services. These Terms of Use are a legally binding contract between you and Neurona regarding your use of the Site. PLEASE READ THE … of the Site; (c) sublicense, distribute, sell, lend, rent, lease, transfer, or grant any rights in or to all or any portion of the Site or provide access to the Site to third parties on a service bureau basis or otherwise; or (d) interfere with or circumvent any feature of the Site, including any security or access control mechanism, or introduce any security threats into or through the Site. If you are prohibited under applicable law from using the Site, you may not use&nbs … o the Site or our business, products, or services (“ Feedback ”) or submit content, Materials, or information through interactive features (“ Content ”), then you hereby grant Neurona an unrestricted, perpetual, irrevocable, non-exclusive, fully-paid, royalty-free right to exploit the Feedback or Content in any manner and for any purpose, including to improve the Site and create or improve other products and services. 6. Ownersh … D ON THE SITE. THE LIMITATIONS, EXCLUSIONS AND DISCLAIMERS IN THIS SECTION APPLY TO THE FULLEST EXTENT PERMITTED BY LAW. NEURONA DOES NOT DISCLAIM ANY WARRANTY OR OTHER RIGHT THAT NEURONA IS PROHIBITED FROM DISCLAIMING UNDER APPLICABLE LAW. 14. Limitation of Liability . TO THE FULLEST EXTENT PERMITTED BY LAW, IN NO EVENT WILL NEURONA BE LIABLE TO YOU FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES (INCLUDING DAM … OF ALL OTHER PROVISIONS OF THESE TERMS. THE LIMITATIONS IN THIS SECTION 14 WILL APPLY EVEN IF ANY LIMITED REMEDY FAILS OF ITS ESSENTIAL PURPOSE. 15. Governing Law . These Terms are governed by the laws of the State of California without regard to conflict of law principles. All disputes arising out of these Terms are subje
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press R … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days March 12, 2024 | 1 min read Twitter LinkedIn Facebook Email Print Neurona Therapeutics today announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will present a corporate update on Tuesday, March 19 at 5:00 pm ET and host o … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001 Press Release Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001 – NRTX-1001 is being evaluated in an ongoing Phase I/II clinical trial in adults with drug-resistant focal epilepsy San Francisco, CA, March 07, 2024 – Neurona Therapeutics , a clinical-stage biotherapeutics compan … 5135091 ). The first part of the clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine ( CIRM ; CLIN2-13355) . With $5.5 billion in funding and more than 150 active stem cell programs in its portfolio, CIRM is one of the world’s largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality. About Neurona Therapeutics Neurona is focused on developing regenerative cell
Marina Bershteyn - 2025sv - PMWC Precision Medicine World Conference Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdow … ogin / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry media / influencer pass CONTACT US ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ GET UPDATES Past Event PMWC, Feb 5-7, 2025 Attend Program Schedule Honorees Speakers Showcases Exhibits + Map Travel Venue Sightseeing Reduced Rates Hotel Flights Login / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to sp … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … tter Facebook Flickr Youtube Open Popup --> × Add Names/PO on Receipt --> Submit Apply to Speak at PMWC Silicon Valley by JUL. 2ND The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details. Name * Email* * Affiliation (Company, Institution, etc) * Inquiry Type * Inquiry Type* Talk/Speaker Inquiry Company Competition Inquiry Showcase Application Exhibition Inquiry General Inquiry Message * Anti-Spam: What is 4 minus 1 ? * … tion, etc) * Inquiry Type* * Inquiry Type* Company Competition Inquiry Showcase Application Talk Inquiry Exhibition Inquiry General Inquiry Message * Example (do not send as is!): My company is at the Seed, or Series A stage, and I would like to receive the Company Competition form. Anti-Spam: What is 4 minus 1 ? * Phone This field is for validat
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE) Press Release Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE) – NRTX-1001 investigational treatment has been well tolerated in all initial subjects – Positive decision from data safety monitoring board (DSMB) on review of first cohort safety data greenlights dos … 5135091 ). The first part of the clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355) . With $5.5 billion in funding and more than 150 active stem cell programs in its portfolio, CIRM is one of the world’s largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality. About NRTX-1001 NRTX-1001 is a regenerative neural cell therapy candidate derive
Big Pharma Deals & FDA Approvals: Eli Lilly, UCB, Sanofi | Joanna Sadowska, PhD, EMBA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All … n Brain Communications. One manuscript reports... UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to... More Releases From This Source Explore Health Care & Hospitals Medical Pharmaceuticals Pharmaceuticals Biotechnology News Releases in Similar Topics … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Neurona Acquired by UCB for Epilepsy Treatments | Erica Whittaker posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer Press Release Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer San Francisco, CA, July 31, 2023 – Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the appointment of James Stutz, a business and finance executive with over 20 years of experience in the biopharma industry, as chief financial officer (CFO) and chief busines
Neurona Therapeutics to be Acquired by UCB – Ysios Capital About us About us Funds Investment strategy Our portfolio The team The team Join us News & events Impact/ESG ESG Y-mpact Measure your Y-score Contact us Investors login 17 April 2026 UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science Acquisition builds on UCB’s 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies. Lead investigational asset, NRTX-1001, a neuronal cell therapy, is being evalua
Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders Press Release Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders – Syndicate includes premier healthcare investors steeped in neurology – Erica Whittaker, Ph.D., head of UCB Ventures, joins Neurona’s board of directors – Latest financing brings total proceeds raised to date to $135 million San Francisco, CA, June 22, 2021 & … ures and current investor The Column Group. Other new investors included Sphera Fund Management, Alexandria Venture Investments, and Ironfire Ventures. Neurona also announced that Erica Whittaker, Ph.D., head of UCB Ventures, has joined Neurona’s board of directors. Dr. Whittaker began her career at UCB in 2010 and has led UCB Ventures since its inception. Previously at UCB, she held roles as vice president, research strategy & partnering and head of market access & … ut UCB Ventures UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. UCB Ventures invests in innovative therapeutics and technology platforms that are early stage and higher risk, in areas adjacent to or even beyond UCB’s therapeutic focus on neurology/neurodegenerative
Neurona Therapeutics Acquired by UCB for $1.15B | Raymond J. Kelleher, MD, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … for solid tumours. We thank our investor syndicate Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, High-Tech Gründerfonds (HTGF), Eurazeo, Creathor Ventures, and Thuja Capital. Our Chairman of the Board, Klaus Schollmeier commented: “Tacalyx has delivered on its promise to unlock the therapeutic potential of TACAs, a frontier in oncology that has long been considered undruggable. With the selection of its first clinical candidate and significant advances with its ea
Neurona Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investmen
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate Press Release Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate San Francisco, CA, September 10, 2024 – Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $3.8M grant to support the development of a next generation ne … in drug-resistant epilepsy.” “CIRM is delighted to make this award to Neurona Therapeutics in view of the highly encouraging initial data from its ongoing Phase 1/2 clinical trial in adults with drug-resistant epilepsy. Today’s grant brings CIRM’s cumulative commitment to the company to $18.5M across five separate grants,” said Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM. “This award highlights the promise o … e Phase 1 of the unilateral MTLE clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355) . The FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 in June 2024 based on positive clinical data from the ongoing Phase 1/2 trial in unilateral MTLE, for which the most recent data update was presented at the American Academy of Neurology Annual Meeting in April 2024. In Febru
BioTech Nation ... with Dr. Moira Gunn | PART 1: A Regenerative Leap for Epilepsy…Dr. Cory Nicholas, Co-Founder and CEO, Neurona Therapeutics BioTech Nation ... with Dr. Moira Gunn Home Episodes About Dr. Gunn Media Info JPM 2026 BTN "5" BIO 2026 Subscribe menu close Home Episodes About Dr. Gunn Media Info JPM 2026 BTN "5" BIO 2026 Subscribe play pause PART 1: A Regenerative Leap for Epilepsy…Dr. Cory Nicholas, Co-Founder and CEO, Neurona Therapeutics May 14, 2025 / 23:48 / E25019 Show Notes / Transcript This week on BioTech Nation, Dr. Cory Nicholas, Co-Founder and CEO of
2026 Annual Meeting | S41 - Epilepsy: Public Health and Epidemiology American Academy of Neurology: Neurology Resources | AAN AAN Publications Explore the latest content from across our publications AAN Publications Donate To Research Join The AAN Log In Education Education Education Online Learning Center CME Opportunities NeuroTracker Leadership Programs Education Awards & Scholarships Podcasts Discover learning and leadership opportunities, earn CME, and track credits. See All Research Research Research Abstracts Publications Awards Research Programs & Grants Donate to Research Expl … ams & Grants Donate to Research Explore prestigious scientific journals and award and funding opportunities to advance your research. See All Practice Practice Practice Guidelines Quality Measures Billing & Coding Telehealth Operations Medicare Fee-for-service Benchmarking Clinical Informatics Quality Payment Program Team-based Care Practice Care Models Access practice-improvement tools, including guidelines, measures, and practice management resources. See All Member … ons Event Timeline 01:00 PM - 01:12 PM CDT Speaker 2026 Dreifuss-Penry Epilepsy Award: This award recognizes physicians in the early stages of their careers who have made an independent contribution to epilepsy research Mark R. Keezer, MD, PhD 01:12 PM - 01:24 PM CDT Abstract 002 - Examining the Impact of Comorbid Depression on Healthcare Utilization, Cost, and Outcomes in Patients with Newly Diagnosed Epilepsy in the US Samuel W. Terman, MD 01:24 PM - 01:36 PM CDT Abstract 0 … 0,000-$499,999 for serving as a clinician scientist trainee for Susan S Spencer award with American Academy of Neurology. Manher Joshi, MD Dr. Joshi has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Joshi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Atara Biotherapeutics. Dr. Joshi has stock in Atara Biotherapeutics. Daniela Markovic Daniela Markovic has nothing to disclose. Yecheng … ick has received personal compensation in the range of $0-$499 for serving as a Grant reviewer with Society of Family Planning. Dr. Kirkpatrick has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Norton Children's Hospital. Dr. Kirkpatrick has a non-compensated relationship as a Board of Directors mem
Abstract Details American Academy of Neurology: Neurology Resources | AAN AAN Publications Explore the latest content from across our publications AAN Publications Donate To Research Join The AAN Log In Education Education Education Online Learning Center CME Opportunities NeuroTracker Leadership Programs Education Awards & Scholarships Podcasts Discover learning and leadership opportunities, earn CME, and track credits. See All Research Research Research Abstracts Publications Awards Research Programs & Grants Donate to Research Explore prestigious scientific journals and award and fu
Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference March 8, 2023 | 1 min read Twitter LinkedIn Facebook Email Print Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, a … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Abstract Details American Academy of Neurology: Neurology Resources | AAN AAN Publications Explore the latest content from across our publications AAN Publications Donate To Research Join The AAN Log In Education Education Education Online Learning Center CME Opportunities NeuroTracker Leadership Programs Education Awards & Scholarships Podcasts Discover learning and leadership opportunities, earn CME, and track credits. See All Research Research Research Abstracts Publications Awards Research Programs & Grants Donate to Research Explore prestigious scientific journals and award and fu
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science | UCB Skp to main content Main navigation Menu Innovation Innovation Overview Capabilities Innovation is Pipeline Drug discovery Clinical studies Publications You might be interested in... Page Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity Page Publications - A dedicated space where we share a collection of our scientific peer-reviewed... Page Pipeline - Check out our clinical development pipeline spanning several therapy areas Sol … Direct access to our latest annual report Story 9 Feb 2026 UCB Community Health Fund enters a new phase Page UCBCares® - Discover what UCBCares® is about and the services they offer Newsroom Newsroom Overview Press releases Our stories Resources Contact details You might be interested in... Press Release 11 Mar 2026 BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study... Press Release 26 Feb 2026 Strong Execution Fueling Sustaine
A Conversation with CEO Cory Nicholas on Neurona Therapeutics’ Recent RMAT Designation - The Stem Cellar The Stem Cellar The Official Blog of CIRM, California's Stem Cell Agency Menu Skip to content Home Disease Research News/Events CIRM News Events Ethics/Policy Weekly Roundup Features 10 Years of iPSCs CIRM Fights Cancer CIRM Scholars Genes + Cells Month of CIRM Profiles in Courage Stories of Hope Throwback Thursday About CIRM Archived: Stem Cellar Team Search Search for: A Conversation with CEO Cory Nicholas on Neurona Therapeutics’ Recent RMAT Designation August 15, 2024 August 20, 20
UCB’s $1.15 billion acquisition of... - Industry Examiner Facebook Log In Industry Examiner's Post Industry Examiner Verified account April 21 · Shared with Public UCB’s $1.15 billion acquisition of Neurona Therapeutics is about more than a single biotech deal. It is a wager that epilepsy treatment can move beyond symptom control and toward targeted neural repair. In our latest feature, we look at why this transaction matters, what NRTX-1001’s early data do and do not prove, why specialized epilepsy centers will be central to adoption, and what this says about cell therapy’s push beyond o
Stem cell research hints at evolution of human brain – Popular Archeology Discoveries Digs Daily News Promotion Reports Viewpoints About Us Issues Archive Advertise Log In Home About Us Adopt a Site Discovering Ancient Tibet Nojol Nah Authors Issues Archive Advertise Join Popular Archaeology Log In Discoveries Digs Daily News Promotion Reports Viewpoints About Us Issues Archive Advertise Log In --> Menu Spring 2026 Issue Daily News Stem cell research hints at evolution of human brain By No Author Thu, Sep 24, 2015 SHARE ON: Twitter Facebook University of California – San Francisco
UCSF Spinoff, Bay Area’s Neurona Therapeutics, Launches With $23.5 Million Series A Round - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Thera … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business UCSF Spinoff, Bay Area’s Neurona Therapeutics, Launches With $23.5 Million Series A Round December 3, 2015 | 2 min read Twitter LinkedIn Facebook Email Print Lukas Roth December 3, 2015 By Mark Terry , BioSpace.com Breaking News Staff The Bay Area hosts another new biotech startup today, as N … . This makes them less likely become tumor cells. The Column Group is a venture fund that takes a slightly different approach to biotech startups. It typically uses its money to build its own companies, rather than fund someone else’s company. It was formed in 2007 and has invested in about a dozen companies, including Neurona . Its startups have included Aragon Pharmaceuticals , which sold to Johnson & Johnson Innovation in 2013 for $1 billion in cash and milestone payme … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Uncertainty and excitement surround one company’s cell therapy for epilepsy | The Transmitter: Neuroscience News and Perspectives Skip to content Open search form Close menu Close search form Menu Open menu Close menu Close menu News Perspectives Features Profiles This paper changed my life Podcasts Books Events Courses Spectrum logo AI: From bench to bot Autism prevalence Brain imaging Computational neuroscience Craft and careers Funding and policy How to teach this paper Neural circuits NeuroAI Open neuroscience and data-sharing Systems neuroscience Science and society See all topics About T … approved that addition to the trial last December. Neurona is also planning to submit a protocol for a trial for people with bilateral focal epilepsy later this year. The company plans to eventually run a placebo-controlled trial of NRTX-1001. W hether Neurona succeeds with the trials or not, “we’re entering a new phase” for treating neurological conditions, says Kim Burchiel , professor of neurological surgery at Oregon Health & Science University in Portland, who perfo … ou missed from our recent coverage, and get breaking news alerts. Email Address Submit tags: Interneurons , Animal models , Audio research news , Autism , Circuits , Clinical trials , Epilepsy , Inhibitory signaling , Seizures , Treatments Explore more from The Transmitter Locomotion comments Remembering Avis H. Cohen, who bridged disciplines to decode lamprey locomotion By Sarah Thau 26 June 2026 | 8 min read When autistic kids grow up Microphone comments When autistic kids
Neurona Therapeutics Announces C-Suite Leadership Team --> Accessibility: Skip TopNav Neurona Therapeutics Announces C-Suite Leadership Team December 13, 2021 08:00 ET | Source: Neurona Therapeutics Neurona Therapeutics SAN FRANCISCO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced three promotions within its leadership team: Catherine Priest, Ph.D., previously Neurona’s vice president of preclinical development, has been appointed to chi … the California Institute for Regenerative Medicine (CIRM), where she managed a grant portfolio of translational and clinical programs. Previously, Dr. Priest led the preclinical cellular therapeutics group at Geron Corporation, working on treatments for spinal cord injury, cardiovascular disease and diabetes. During that time, Geron developed the first successful IND application for an embryonic stem cell-derived cellular therapeutic that was approved by the U.S. Food and Dr … his M.D. from the University of California at San Diego and completed neurology residency and neurophysiology fellowship at the University of California at Los Angeles. About Neurona’s Phase 1/2 clinical trial of NRTX-1001 for MTLE Neurona’s multi-center, Phase 1/2 clinical trial is designed to evaluate the safety, tolerability, and efficacy of a single administration of NRTX-1001 for drug-resistant mesial temporal lobe epilepsy (MTLE). The first stage of the trial is an open
phase 3 epic epilepsy cell therapy clinical trial design: nrtx-1001 gabaergic interneuron cell therapy for the treatment of drug-resistant unilateral mesial temporal lobe epilepsy mtle Career Center AES Connect Donate supervisor_account check_circle Get Involved search search Search menu Menu Home Abstracts Abstracts Phase 3 EPIC (EPIlepsy Cell Therapy) Clinical Trial Design: NRTX-1001 GABAergic Interneuron Cell Therapy for the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE) Abstract number : 3.285 Submission category : 4. Clinical Epilepsy / 4C. Clinical Treatments … ucation arrow_drop_down AES Learn Resident Courses Epilepsy and Neurophysiology Fellowship Match Membership arrow_drop_down Become a Member Get Involved In Memoriam Directory (Members Only) Give arrow_drop_down Make a Gift Planned Giving Your Dollars at Work Targeted Funds Corporate Support About arrow_drop_down About AES Publications & Reports Press Room Reach Members Epilepsy Leadership Council Contact AES arrow_upward Back to top Terms of Use Disclosure P
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline Press Release Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline – The oversubscribed private financing round, with primary participation from Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, and Cormorant Asset Management, follows continued positive clinical signal from Neurona’s ongoing Phase 1/2 clinical trial &n … ngle pivotal trial and is intended to support submission of a Biologics License Application (BLA) South San Francisco, CA, April 3, 2025 – Neurona Therapeutics , a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an upsized and oversubscribed $102 million financing. New and existing investors in the financing round include Fidelity … B Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, and Spur Capital Partners. Proceeds from the financing will be used to advance the company’s wholly owned pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead investigational candidate, NRTX-1001, for drug-resistant mesial temporal lobe epilepsy (MTLE), which is among the most common … e. The Phase 1/2 unilateral MTLE clinical trial is supported by an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM; CLIN2-13355). The FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to NRTX-1001 in June 2024. For more information about Neurona, visit: www.neuronatherapeutics.com . Investor Contact: Laurence Watts New Street Investor Relations [email protected] Back to Press Releases About Mission / Vision Leade
--> » UCB to purchase Neurona and NRTX-1001 for $1.15bn --> --> UCB to buy Neurona and NRTX-1001 for $1.15bn Pharmaceutical Business review is using cookies Continue Learn More Close ☰ Search × Home About Us Add Company Advertise with us Contact us Events Suplpiers News Clinical Trials Drug Discovery Packaging & Supply Chain Production & Sales Regulation Advertise With Us Advertise on our extensive network of industry websites and newsletters. Get the PBR newsletter Sign up to our free email to get all the latest PBR news. Home Drug Discovery Drug Discovery Research … t Enrollment Human Trials Patient Enrollment US FDA approves Avacta Group’s IND application for AVA6000 Clinical Trials Patient Enrollment AM-Pharma enrols first patients in Covid-19 phase III trial Clinical Trials Patient Enrollment Regulation Regulation Drug Filing Approvals Rejections Marketing Authorisation Patents Lawsuits Drug Filing Viatris files applications in Japan for approval of Effexor to treat GAD Regulation Drug Filing Drug Manufacturing Scholar Rock submits ap
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs Press Release Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs San Francisco, CA, June 26, 2024 – Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Nadia Agopyan, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. “We are thrilled to have Nadia join Neurona as a strong addition to our senior leadership team,&rdqu … be joining Neurona, particularly in light of the FDA’s recent decision to award NRTX-1001 its RMAT designation, and the highly positive data coming out of the ongoing Phase 1/2 trial Neurona is conducting in drug-resistant temporal lobe epilepsy,” said Nadia Agopyan, Senior Vice President of Regulatory Affairs at Neurona Therapeutics. “There is a high unmet medical need in refractory focal epilepsy, and NRTX-1001 potentially represents a breakthrough, with t
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > stream x�S(�5г4�07U0A$vr.��[���K>�B���c endstream endobj 5 0 obj > endobj 6 0 obj >/Type /Page>> endobj 7 0 obj >/Font >/ProcSet [/PDF /Text /ImageC]/XObject >>>/Subtype /Form/Type /XObject>> stream x��\ko 9v��>���6��"`8�ei2�ggF�Y�YZ�e�N�1�'��s�%Y�ꇬ� ��0�n �}�%Y�/�j��χF7��g����� �������ɛ��j�O7?O^|�Ư'/������d�� _.��� ����F��E����[�q S���o�mo��ܛ$*����lɾ�D�� ��A��Ϟ������ZiK����5�q,>~{ f� ܔ BϓΈ�뼒�J�몌�g�lW�}�� ��S��@��;� ]�j��g��'̼�#C����������~wxd�����_ � r>_b�!J�e.�~��ٳIO����v��ݩ$v�j��(�UW ��'n �ʣ�